Literature DB >> 28405766

Characterization of cross-clade monoclonal antibodies against H5N1 highly pathogenic avian influenza virus and their application to the antigenic analysis of diverse H5 subtype viruses.

Dulyatad Gronsang1,2, Anh N Bui3, Dai Q Trinh3, Vuong N Bui3, Khong V Nguyen3, Minh X Can3,4, Tsutomu Omatsu5, Tetsuya Mizutani5, Makoto Nagai5,6, Yukie Katayama5, Rapeewan Thampaisarn1,2, Haruko Ogawa1, Kunitoshi Imai7.   

Abstract

H5N1 highly pathogenic avian influenza viruses (HPAIVs) are a threat to both animal and public health and require specific and rapid detection for prompt disease control. We produced three neutralizing anti-hemagglutinin (HA) monoclonal antibodies (mAbs) using two clades (2.2 and 2.5) of the H5N1 HPAIV isolated in Japan. Blocking immunofluorescence tests showed that each mAb recognized different epitopes; 3B5.1 and 3B5.2 mAbs against the clade 2.5 virus showed cross-clade reactivity to all 26 strains from clades 1, 2.2, 2.3.2.1, 2.3.2.1a, b, c and 2.3.4, suggesting that the epitope(s) recognized are conserved. Conversely, the 1G5 mAb against the clade 2.2 virus showed reactivity to only clades 1, 2.3.4 and 2.5 strains. An analysis of escape mutants, and some clades of the H5N1 viruses recognized by 3B5.1 and 3B5.2 mAbs, suggested that the mAbs bind to an epitope, including amino acid residues at position 162 in the HA1 protein (R162 and K162). Unexpectedly, however, when five Eurasian-origin H5 low-pathogenic AIV (LPAIV) strains with R162 were examined (EA-nonGsGD clade) as well as two American-origin strains (Am-nonGsGD clade), the mAb recognized only EA-nonGsGD clade strains. The R162 and K162 residues in the HA1 protein were highly conserved among 36 of the 43 H5N1 clades reported, including clades 2.3.2.1a and 2.3.2.1c that are currently circulating in Asia, Africa and Europe. The amino acid residues (158-PTIKRSYNNTNQE-170) in the HA1 protein are probably an epitope responsible for the cross-clade reactivity of the mAbs, considering the epitopes reported elsewhere. The 3B5.1 and 3B5.2 mAbs may be useful for the specific detection of H5N1 HPAIVs circulating in the field.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28405766     DOI: 10.1007/s00705-017-3350-0

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  5 in total

1.  Structural and functional definition of a vulnerable site on the hemagglutinin of highly pathogenic avian influenza A virus H5N1.

Authors:  Pengfei Wang; Yanan Zuo; Jianfeng Sun; Teng Zuo; Senyan Zhang; Shichun Guo; Xuanling Shi; Mifang Liang; Paul Zhou; Linqi Zhang; Xinquan Wang
Journal:  J Biol Chem       Date:  2019-02-08       Impact factor: 5.157

2.  A fluorescence polarization immunoassay for the rapid detection of antibody against influenza A virus in chicken and goat sera.

Authors:  Yohei Takeda; Yutaka Yonezawa; Satoshi Asake; Haruko Ogawa; Kunitoshi Imai
Journal:  J Vet Diagn Invest       Date:  2020-10-07       Impact factor: 1.279

3.  Complementary recognition of the receptor-binding site of highly pathogenic H5N1 influenza viruses by two human neutralizing antibodies.

Authors:  Yanan Zuo; Pengfei Wang; Jianfeng Sun; Shichun Guo; Guiqin Wang; Teng Zuo; Shilong Fan; Paul Zhou; Mifang Liang; Xuanling Shi; Xinquan Wang; Linqi Zhang
Journal:  J Biol Chem       Date:  2018-08-28       Impact factor: 5.157

4.  Production of highly and broad-range specific monoclonal antibodies against hemagglutinin of H5-subtype avian influenza viruses and their differentiation by mass spectrometry.

Authors:  Violetta Sączyńska; Anna Bierczyńska-Krzysik; Violetta Cecuda-Adamczewska; Piotr Baran; Anna Porębska; Katarzyna Florys; Marcin Zieliński; Grażyna Płucienniczak
Journal:  Virol J       Date:  2018-01-15       Impact factor: 4.099

Review 5.  Targeting Hemagglutinin: Approaches for Broad Protection against the Influenza A Virus.

Authors:  Yun Zhang; Cong Xu; Hao Zhang; George Dacai Liu; Chunyi Xue; Yongchang Cao
Journal:  Viruses       Date:  2019-04-30       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.